A Phase 1 Study to Evaluate the Pharmacokinetics and the Pharmacodynamics of TH9507 Administered Subcutaneously Once Daily for 14 Consecutive Days in HIV Positive Patients
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Tesamorelin (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Theratechnologies
- 19 Dec 2013 New trial record